Clear cell renal cell carcinoma (ccRCC) is a malignancy characterized by deregulated hypoxia-inducible factor signaling, mutation of several key chromatin modifying enzymes, and numerous alterations in cellular metabolism. Pre-clinical studies have historically been limited to cell culture models, however, the identification of critical tumor suppressors and oncogenes from large-scale patient sequencing data has led to several new genetically engineered mouse models with phenotypes reminiscent of ccRCC. In this review, we summarize recent literature on these topics and discuss how they inform targeted therapeutic approaches for the treatment of ccRCC.
Biochimica et biophysica acta. 2018 Jun 27 [Epub ahead of print]
Danielle J Sanchez, M Celeste Simon
Abramson Family Cancer Research Institute, 456 BRB II/III, 421 Curie Boulevard, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Cell and Developmental Biology, 456 BRB II/III, 421 Curie Boulevard, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6160, USA., Abramson Family Cancer Research Institute, 456 BRB II/III, 421 Curie Boulevard, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Cell and Developmental Biology, 456 BRB II/III, 421 Curie Boulevard, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6160, USA. Electronic address: .